An observational study in Septic Shock, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by CHU de Reims · Observational
Previous studies of our team reported the improvement of myocardial contractility both on hemodynamic parameters (by transpulmonary thermodilution) and morphological (by transthoracic echocardiography: TTE), during the early phase of septic shock (during the first 4 hours management of septic shock).
However, one can wonder about the effect of NAD on myocardial cardiac ouput and contractility beyond the early phase of septic shock, more precisely beyond the first 24 hours. Indeed, while it continues to act on the "stressed" blood volume and the diastolic left ventricular perfusion by increasing the diastolic arterial pressure (DAP), it has been reported in old studies that beyond the early phase, the sensitivity of the β1-adrenergic receptors is altered due to the phenomenon of internalization of these receptors, leading to a reduction of the myocardial response to catecholamines.
The investigators can then wonder whether norepinephrine still exerts a positive effect on myocardial contractility via the increase in DAP, despite an alteration of the β1-adrenergic pathway.
To answer this question, the investigators proposed to evaluate the effects of norepinephrine by TTE on cardiac contractility after the initial phase.
Patients presenting with septic shock for 24 hours or more and meeting the inclusion criteria may be included.
The course of the study will be as follows:
T0: collection (as part of usual care) of clinical circulatory parameters (heart rate, systolic/diastolic/mean blood pressure) and biological parameters (arterial lactate and ScVo2) and performance of echocardiography.
Parameters collected during TTE:
Concerning the main judgment criterion and the secondary judgment criteria:
Other parameters collected systematically:
T1: After the clinician in charge introduces or increases norepinephrine to achieve MAP ≥ 65mmHg, T1 will be when the goal of MAP ≥ 65mmHg is reached. This will be the target MAP for the management of septic shock of the patient in question according to the recommendations of learned societies.
Collection of clinical and biological circulatory parameters and performance of the TTE. The parameters collected will be the same as at T0.
862 studies on the registry are indexed under Shock, Septic; 207 are open to participants now.
This study's planned enrollment of 49 is below the median of 100 across 298 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →CHU de Reims is the lead sponsor of 267 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients suffering from septic shock, after 24 hours of their diagnosis. Presenting with Mean arterial pressure (MAP)\<65 mmHg or the target MAP For whom the physician in charge decided to increase the norepinephrine dose
Exclusion Criteria:
Adult patients suffering from septic shock, after 24 hours of their diagnosis. Presenting with Mean arterial pressure (MAP)\<65 mmHg or the target MAP For whom the physician in charge decided to increase the norepinephrine dose
Other: transthoracic echocardiography
* Concerning the main judgment criterion and the secondary judgment criteria: * Left ventricular ejection fraction (LVEF) by the Simpson Biplane method, * Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)). * Tricuspid Annular Systolic Excursion (TAPSE) (mm) * S wave at the tricuspid ring (cm/s) * Other parameters collected systematically: * Surface of the left ventricle (end-systolic and end-diastolic), * Global strain of the left ventricle * Mitral Annular Plane Systolic Excursion (MAPSE) (mm) * Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e'); * Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)
The effect of the increase of Norepinephrine dose after restoring MAP on cardiac contractility evaluated by TTE : the left ventricular ejection fraction
Time frame: through study completion, an average of 30 minutes
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHU de Reims